Yahoo Finance Plus President Joe Biden said he will raise the issue of human rights in his upcoming meeting with Saudi Crown Prince Mohammed Bin Salman, but did not commit to specifically bringing up the murder of columnist Jamal Khashoggi. "I always bring up human rights, but my position on Khashoggi has been so clear, if anyone doesn't understand it in Saudi Arabia or otherwise they haven't been around me for a while," Biden told reporters in Jerusalem.
Harriet Hageman says the Wyoming representative didn't actually concede after losing on Election Night, but Cheney has the receipts
In this article, we discuss the 5 stocks that Warren Buffett is buying on the dip. If you want to see more stocks in this selection, click Warren Buffett is Buying the Dip on These 3 Stocks. Berkshire Hathaway’s Warren Buffett went on a buying spree despite the turmoil in the global equity markets. In […]
Yahoo Finance Live’s Brian Cheung and Brian Sozzi discuss why retail traders are angry at activist investor Ryan Cohen for selling his remaining stake in BBBY stock.
Shares of StoneCo (NASDAQ: STNE), a cloud-based technology platform, plummeted Friday morning after the company reported its second-quarter results, which disappointed investors, and announced yet another shift to its management team. The company reported non-GAAP (adjusted) earnings of 0.25 Brazilian reals (equivalent to $0.05), which was an increase from a loss of 0.48 reals in the year-ago quarter, but was below Wall Street's consensus estimate of about 0.57 reals, or $0.11 per share. StoneCo's revenue in the quarter was 2.3 billion reals (about $442 million), 5% higher than the company's guidance, and up 275% from the year-ago quarter.
A lot of surprising companies are paring back their payrolls lately. Some of them should bounce back soon.
The European Medicines Agency (EMA) has validated Aeglea BioTherapeutics Inc's (NASDAQ: AGLE) marketing application seeking approval for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D). Arginase deficiency is an inherited disorder that causes the amino acid arginine (a building block of proteins) and ammonia to accumulate gradually in the blood. Ammonia, formed when proteins are broken down in the body, is toxic if levels become too high. Related: Aeglea BioTherapeutics Shares
Yahoo Finance's Brian Cheung discusses reports that a depression drug from Axsome Therapeutics has gotten FDA clearance.
(Bloomberg) -- The US mortgage industry is seeing its first lenders go out of business after a sudden spike in lending rates, and the wave of failures that’s coming could be the worst since the housing bubble burst about 15 years ago. Most Read from BloombergXi and Putin to Attend G-20 Summit in Indonesia, Jokowi SaysApple Targets Sept. 7 for iPhone 14 Launch in Flurry of New DevicesUS Mortgage Lenders Are Starting to Go BrokeCovid’s Harmful Effects on the Brain Reverberate Years LaterBiden's Ne
Verizon (VZ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
How much money people have put away for retirement naturally varies by age. See how your savings stack up.
For investors looking to maximize their wealth by the time they retire, the following pair of beaten-down businesses that possess strong growth capabilities are a worthwhile place to start. Freelance marketplace operator Fiverr (NYSE: FVRR) was a pandemic-lockdown superstar. Although Fiverr's stock price is down 65% in 2022 and off 82% from its all-time high, the freelance shop is still growing, albeit at a slower rate as SMBs became more cautious due to rampant inflation and rising energy costs and interest rates.
Journal of Prevention of Alzheimer's Disease (JPAD) informed Cassava Sciences Inc (NASDAQ: SAVA) about no convincing evidence to support data manipulation allegations in a 2020 paper on simufilam co-authored by the company's personnel and its science collaborators. Simufilam, Cassava's Alzheimer's candidate, is a small molecule (oral) drug that restores the normal shape and function of altered filamin A protein in the brain. "From the onset, I have said that allegations of research misconduct ar
The past few weeks have been refreshing for Cathie Wood and fans of her style of growth stock investing. The CEO and co-founder of Ark Invest publishes the buys and sells of her firm's exchange-traded funds (ETFs) every market day, giving the public insight into her latest allocation strategies.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BlackCloak CEO Chris Pierson joins Yahoo Finance Live to discuss Apple’s security vulnerabilities, why Apple users should update their devices, and the outlook for cyberattacks.
(Bloomberg) -- Billionaire Ryan Cohen pocketed a $68.1 million profit from the sale of his stake in Bed Bath & Beyond Inc., scoring a 56% gain on an investment he held for roughly seven months.Most Read from BloombergXi and Putin to Attend G-20 Summit in Indonesia, Jokowi SaysApple Targets Sept. 7 for iPhone 14 Launch in Flurry of New DevicesUS Mortgage Lenders Are Starting to Go BrokeCovid’s Harmful Effects on the Brain Reverberate Years LaterBiden's Next Grand Bargain Could Retire TrumpThe ret
Yahoo Finance anchors report that Bed Bath & Beyond stock tanked on Friday morning, falling by the most since January 2021.
In this article, we will take a look at the top 10 stock picks of Osman Ozsan’s Deuterium Capital Management. If you want to skip our discussion of Deuterium Capital Management’s history, investment philosophy, and hedge fund preference, go directly to Top 5 Stock Picks of Osman Ozsan’s Deuterium Capital Management. Deuterium Capital Management, LLC […]
Yahoo Finance Live anchors discuss Bed Bath & Beyond stock performance after activist investor Ryan Cohen completes his sale of shares.
The stock price of the specialist in central nervous system disorders is shooting higher today in response to the Food and Drug Administration's (FDA) approval of its major depressive disorder (MDD) drug Auvelity. Auvelity has been under review with the FDA for well over a year at this point. The drug's review took longer than expected due to issues with the analytical methods in the Chemistry, Manufacturing, and Controls section of its regulatory application.
Yahoo Finance